

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <b>BAKER JULIAN</b>  (Last) (First) (Middle) <b>667 MADISON AVENUE, 21ST FLOOR</b>  (Street) <b>NEW YORK NY 10065</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>INCYTE CORP [ INCY ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <b>03/15/2016</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock							58,632 <sup>(1)</sup>	D		
Common Stock							61,049 <sup>(2)</sup>	D		
Common Stock							33,410	I	See Footnotes <sup>(3)</sup>	
Common Stock							513,020	I	See Footnotes <sup>(4)(20)</sup>	
Common Stock	03/15/2016		P		19,642	A	\$67.1476 <sup>(5)</sup>	3,280,026	I	See Footnotes <sup>(6)(20)</sup>
Common Stock	03/15/2016		P		180,358	A	\$67.1476 <sup>(5)</sup>	19,196,210	I	See Footnotes <sup>(7)(20)</sup>
Common Stock	03/15/2016		P		19,513	A	\$65.7978 <sup>(8)</sup>	3,299,539	I	See Footnotes <sup>(6)(20)</sup>
Common Stock	03/15/2016		P		179,176	A	\$65.7978 <sup>(8)</sup>	19,375,386	I	See Footnotes <sup>(7)(20)</sup>
Common Stock	03/15/2016		P		129	A	\$65.2924 <sup>(9)</sup>	3,299,668	I	See Footnotes <sup>(6)(20)</sup>
Common Stock	03/15/2016		P		1,182	A	\$65.2924 <sup>(9)</sup>	19,376,568	I	See Footnotes <sup>(7)(20)</sup>
Common Stock	03/17/2016		M		20,000	A	\$3.86	3,319,668	I	See Footnotes <sup>(10)(11)(15)(16)(20)</sup>
Common Stock	03/17/2016		M		20,000	A	\$3.86	19,396,568	I	See Footnotes <sup>(11)(12)(15)(17)(18)(20)</sup>
Common Stock	03/17/2016		M		20,000	A	\$3.86	533,020	I	See Footnotes <sup>(11)(13)(15)(18)(19)(20)</sup>
Common Stock	03/17/2016		P		10,616	A	\$60.8506 <sup>(21)</sup>	3,330,284	I	See Footnotes <sup>(16)(20)</sup>
Common Stock	03/17/2016		P		97,484	A	\$60.8506 <sup>(21)</sup>	19,494,052	I	See Footnotes <sup>(17)(18)(20)</sup>
Common Stock	03/17/2016		P		2,250	A	\$60.9506 <sup>(22)</sup>	3,332,534	I	See Footnotes <sup>(16)(20)</sup>
Common Stock	03/17/2016		P		20,659	A	\$60.9506 <sup>(22)</sup>	19,514,711	I	See Footnotes <sup>(17)(18)(20)</sup>
Common Stock	03/17/2016		P		2,660	A	\$61.028 <sup>(23)</sup>	3,335,194	I	See Footnotes <sup>(16)(20)</sup>
Common Stock	03/17/2016		P		24,431	A	\$61.028 <sup>(23)</sup>	19,539,142	I	See Footnotes <sup>(17)(18)(20)</sup>
Common Stock	03/17/2016		P		13,936	A	\$61.3778 <sup>(24)</sup>	3,349,130	I	See Footnotes <sup>(16)(20)</sup>
Common Stock	03/17/2016		P		127,964	A	\$61.3778 <sup>(24)</sup>	19,667,106	I	See Footnotes <sup>(17)(18)(20)</sup>
Common Stock	03/17/2016		P		9,821	A	\$62.5869 <sup>(25)</sup>	3,358,951	I	See Footnotes <sup>(16)(20)</sup>
Common Stock	03/17/2016		P		90,179	A	\$62.5869 <sup>(25)</sup>	19,757,285	I	See Footnotes <sup>(17)(18)(20)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Ownership (Instr. 4)
--	--	--------------------------------------	--	--------------------------------	--	--	---	--	--	---	---

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	A	D	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
																(Instr. 8)
Non-Qualified Stock Options (right to buy)	\$3.86	03/17/2016		M				20,000	05/23/2007	05/22/2016	Common Stock	20,000	\$0 <sup>(14)</sup>	0	I <sup>(10)(15)</sup>	See Footnotes
Non-Qualified Stock Options (right to buy)	\$3.86	03/17/2016		M				20,000	05/23/2007	05/22/2016	Common Stock	20,000	\$0 <sup>(14)</sup>	0	I <sup>(12)(15)</sup>	See Footnotes
Non-Qualified Stock Options (right to buy)	\$3.86	03/17/2016		M				20,000	05/23/2007	05/22/2016	Common Stock	20,000	\$0 <sup>(14)</sup>	0	I <sup>(13)(15)</sup>	See Footnotes

1. Name and Address of Reporting Person\*

[BAKER JULIAN](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)

NEW YORK NY 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[BAKER FELIX](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)

NEW YORK NY 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[BAKER BROS. ADVISORS LP](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)

NEW YORK NY 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[667, L.P.](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)

NEW YORK NY 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

## Baker Brothers Life Sciences LP

(Last) (First) (Middle)

667 MADISION AVENUE, 21ST FLOOR

(Street)

NEW YORK NY 10065

(City) (State) (Zip)

### 1. Name and Address of Reporting Person\*

14159, L.P.

(Last) (First) (Middle)

667 MADISION AVENUE, 21ST FLOOR

(Street)

NEW YORK NY 10065

(City) (State) (Zip)

### 1. Name and Address of Reporting Person\*

Baker Bros. Advisors (GP) LLC

(Last) (First) (Middle)

667 MADISION AVENUE, 21ST FLOOR

(Street)

NEW YORK NY New York

(City) (State) (Zip)

### Explanation of Responses:

1. Reflects shares of common stock of Incyte Corporation (the "Issuer") held directly by Julian C. Baker.
2. Reflects shares of common stock of the Issuer held directly by Felix J. Baker.
3. Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in 33,410 shares of Common Stock of the Issuer directly held by FBB Associates. Julian C. Baker and Felix J. Baker are the sole partners of FBB Associates. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Julian C. Baker or Felix J. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
4. As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 513,020 shares of common stock of the Issuer beneficially owned by 14159, L.P. ("14159"), a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 529 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 55,000 shares received previously from exercise of 55,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
5. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$66.60 to \$67.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
6. After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 529 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 55,000 shares received previously from exercise of 55,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
7. After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 14159 and 667, the "Funds"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 529 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 55,000 shares received previously from exercise of 55,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
8. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$65.32 to \$66.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
9. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$65.29 to \$65.295, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
10. As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 20,000 shares of Common Stock of the Issuer received upon the exercise of stock options of the Issuer held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. The policy of the Funds and the Adviser (defined below), does not permit employees or principals of the Adviser to receive compensation for serving as Directors of the Issuer.
11. The shares of common stock were received upon exercise of 20,000 stock options that were issued to Julian C. Baker in his capacity as a director of the Issuer. Julian C. Baker, pursuant to the policies of the Adviser, does not have any right to the pecuniary interest in the stock options issued for his service on the Board or the shares of common stock received upon exercise of such stock options. Each of the Funds owns an indirect proportionate pecuniary interest in the shares of common stock received upon exercise of the stock options issued in connection with Julian C. Baker's service on the Board less the exercise cost of those options. Solely as a result of their ownership interest in the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares issued upon exercise of the stock options (i.e. no direct pecuniary interest).
12. As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 20,000 shares of Common Stock of the Issuer received upon the exercise of stock options of the Issuer held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. The policy of the Funds and the Adviser (defined below), does not permit employees or principals of the Adviser to receive compensation for serving as Directors of the Issuer.
13. As a result of their ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 20,000 shares of Common Stock of the Issuer received upon the exercise of stock options of the Issuer held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. The policy of the Funds and the Adviser (defined below), does not permit employees or principals of the Adviser to receive compensation for serving as Directors of the Issuer.
14. These non-qualified stock options are not priced.
15. The disclosure of the exercise of directors options for shares of common stock reported on this form is a single exercise of 20,000 shares. The 20,000 shares is reported for each of the Funds as each has an indirect pecuniary interest
16. After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial

ownership of 529 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares, 55,000 of which were received previously, from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

17. After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

18. Includes beneficial ownership of 529 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares, 55,000 of which were received previously, from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

19. After giving effect to the transactions reported herein, and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159, L.P.'s right to receive an allocation of a portion of the profits from 14159.

20. Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

21. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$60.46 to \$60.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

22. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$60.82 to \$60.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

23. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$60.99 to \$61.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

24. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$60.99 to \$61.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

25. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$62.22 to \$63.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

#### Remarks:

Julian C. Baker is a director of Incyte Corporation (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputation of the Issuer.

/s/ Julian C. Baker 03/17/2016

/s/ Felix J. Baker 03/17/2016

By: Baker Bros. Advisors LP,  
Name: Scott L. Lessing, Title: 03/17/2016

President /s/ Scott L. Lessing  
Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
667, L.P., pursuant to authority  
granted by Baker Biotech 03/17/2016

Capital, L.P., GP to 667, L.P.  
Name: Scott L. Lessing, Title:  
President /s/ Scott L. Lessing  
Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
BAKER BROTHERS LIFE  
SCIENCES, L.P., pursuant to  
authority granted by Baker 03/17/2016

Brothers Life Sciences Capital,  
L.P., GP to Baker Brothers Life  
Sciences, L.P Name:Scott L.  
Lessing, Title: President /s/

Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
14159, L.P., pursuant to  
authority granted by 14159 03/17/2016

Capital, L.P., GP to 14159, L.P.  
Name: Scott L. Lessing, Title:  
President /s/ Scott L. Lessing

By: Baker Bros. Advisors (GP),  
LLC, Name: Scott L. Lessing, 03/17/2016  
Title: President /s/ Scott L.  
Lessing

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**